Estradiol enhances cell-associated paraoxonase 1 (PON1) activity in vitro without altering PON1 expression

Biochemical and Biophysical Research Communications

Volumn 397, Issue 3, 2010, Pages 441-446

  Ahmad, Syed ^a   Scott, John E ^a  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

Estradiol; Paraoxonase; PON1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; MESSENGER RNA;

ANIMAL CELL; ARTICLE; CATALYSIS; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; ENZYME STABILITY; FEMALE; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CELL LINE; ENZYME STABILITY; ESTRADIOL; FEMALE; HUMANS; MALE; RATS; SEX FACTORS; UP-REGULATION;

ANIMALIA; RATTUS;

EID: 77954217159     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.05.120     Document Type: Article

References (27)

1. Soran H., Younis N.N., Charlton-Menys V., Durrington P. Variation in paraoxonase-1 activity and atherosclerosis. Curr. Opin. Lipidol. 2009, 20:265-274.
2. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., Fu X., Shao M., Brennan D.M., Ellis S.G., Brennan M.L., Allayee H., Lusis A.J., Hazen S.L. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299:1265-1276.
3. Aviram M., Hardak E., Vaya J., Mahmood S., Milo S., Hoffman A., Billicke S., Draganov D., Rosenblat M. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000, 101:2510-2517.
4. Rosenblat M., Gaidukov L., Khersonsky O., Vaya J., Oren R., Tawfik D.S., Aviram M. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 2006, 281:7657-7665.
5. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 1998, 101:1581-1590.
6. Deakin S., Leviev I., Gomaraschi M., Calabresi L., Franceschini G., James R.W. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem. 2002, 277:4301-4308.
7. Thomas-Moya E., Gianotti M., Llado I., Proenza A.M. Effects of caloric restriction and gender on rat serum paraoxonase 1 activity. J. Nutr. Biochem. 2006, 17:197-203.
8. Thomas-Moya E., Gomez-Perez Y., Fiol M., Gianotti M., Llado I., Proenza A.M. Gender related differences in paraoxonase 1 response to high-fat diet-induced oxidative stress. Obesity 2008, (Silver Spring 1):2232-2238.
9. bin Ali A., Zhang Q., Lim Y.K., Fang D., Retnam L., Lim S.K. Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. Free Radic. Biol. Med. 2003, 34:824-829.
10. Wehner J.M., Murphy-Erdosh C., Smolen A., Smolen T.N. Genetic variation in paraoxonase activity and sensitivity to diisopropylphosphofluoridate in inbred mice. Pharmacol. Biochem. Behav. 1987, 28:317-320.
11. Kiranoglu S., Sinan S., Gencer N., Kockar F., Arslan O. In vivo effects of oral contraceptives on paraoxonase, catalase and carbonic anhydrase enzyme activities on mouse. Biol. Pharm. Bull. 2007, 30:1048-1051.
12. Mueller R.F., Hornung S., Furlong C.E., Anderson J., Giblett E.R., Motulsky A.G. Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. Am. J. Hum. Genet. 1983, 35:393-408.
13. Topcuoglu A., Uzun H., Aydin S., Kahraman N., Vehid S., Zeybek G., Topcuoglu D. The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraoxonase activity in postmenopausal women. Tohoku J. Exp. Med. 2005, 205:79-86.
14. Kumru S., Aydin S., Aras A., Gursu M.F., Gulcu F. Effects of surgical menopause and estrogen replacement therapy on serum paraoxonase activity and plasma malondialdehyde concentration. Gynecol. Obstet. Invest. 2005, 59:108-112.
15. Zago V., Sanguinetti S., Brites F., Berg G., Verona J., Basilio F., Wikinski R., Schreier L. Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women. Atherosclerosis 2004, 177:203-210.
16. Sutherland W.H., Manning P.J., de Jong S.A., Allum A.R., Jones S.D., Williams S.M. Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women. Metabolism 2001, 50:319-324.
17. Kwok S., Selby P.L., McElduff P., Laing I., Mackness B., Mackness M.I., Prais H., Morgan J., Yates A.P., Durrington P.N., Sci F.M. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. Clin. Endocrinol. (Oxf.) 2004, 61:760-767.
18. Fenkci I.V., Serteser M., Fenkci S., Akyol A.M. Effects of intranasal estradiol treatment on serum paraoxonase and lipids in healthy, postmenopausal women. Gynecol. Obstet. Invest. 2006, 61:203-207.
19. Akcay Y.D., Sagin F.G., Sendag F., Oztekin K., Sozmen E.Y. Effects of estrogen-only therapy on LDL oxidation in women with hysterectomy: does paraoxonase genotype play a role?. Maturitas 2006, 53:325-332.
20. Ahmad S., Carter J.J., Scott J.E. A homogeneous cell-based assay for measurement of endogenous paraoxonase 1 activity. Anal. Biochem. 2010, 400:1-9.
21. Connelly P.W., Maguire G.F., Picardo C.M., Teiber J.F., Draganov D. Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. J. Lipid Res. 2008, 49:245-250.
22. Soukharev S., Hammond D.J. A fluorogenic substrate for detection of organophosphatase activity. Anal. Biochem. 2004, 327:140-148.
23. Feingold K.R., Memon R.A., Moser A.H., Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998, 139:307-315.
24. James R.W., Deakin S.P. The contribution of high density lipoprotein apolipoproteins and derivatives to serum paraoxonase-1 activity and function. Adv. Exp. Med. Biol. 2010, 660:173-181.
25. Carruba G. Aromatase in nontumoral and malignant human liver tissues and cells. Ann. NY Acad. Sci. 2009, 1155:187-193.
26. Gaidukov L., Viji R.I., Yacobson S., Rosenblat M., Aviram M., Tawfik D.S. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I. Biochemistry 2010, 49:532-538.
27. Rochu D., Renault F., Clery-Barraud C., Chabriere E., Masson P. Stability of highly purified human paraoxonase (PON1): association with human phosphate binding protein (HPBP) is essential for preserving its active conformation(s). Biochim. Biophys. Acta 2007, 1774:874-883.